Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

BACKGROUND: Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. METHODS: ER-positive early breast cancer patients operated at Ruijin Hosp...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Li, Shuai, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8278709/
https://ncbi.nlm.nih.gov/pubmed/34256710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08555-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki